Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Oxalic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | AR | P10275 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 7/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | ALB | P02768 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1839822 | 0.86 | — | — | |
| Oxalic Acid SCHEMBL7507025 | 0.84 | KDM4E (0.47) | LMNAMEN1KMT2AARPDE4D | |
| SCHEMBL2830618 | 0.75 | MEN1 (0.51) | LMNAMEN1KMT2AARPDE4D | |
| Hydrochloric Acid SCHEMBL1375056 | 0.73 | MEN1 (0.50) | LMNAMEN1KMT2AARPDE4D | |
| SCHEMBL16891682 | 0.73 | P2RX7 (0.48) | LMNAMEN1KMT2AARPDE4D | |
| SCHEMBL16892246 | 0.71 | P2RX7 (0.49) | LMNAMEN1KMT2AARPDE4D | |
| SCHEMBL5337870 | 0.70 | MAPK1 (0.57) | LMNAMEN1KMT2AKDM4EMAPK1 | |
| SCHEMBL2824242 | 0.69 | P2RX7 (0.55) | P2RX7 | |
| SCHEMBL772909 | 0.69 | — | — | |
| Hydrochloric Acid SCHEMBL1999396 | 0.68 | KDM4E (0.60) | LMNAMEN1KMT2AKDM4EMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293768-B2 | Organic compounds | NOVARTIS AG (CH) | 2012-10-23 | — | — | US | disclosed |
| US-20120004164-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2012-01-05 | — | — | US | disclosed |
| US-8063084-B2 | Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels | NOVARTIS AG (CH) | 2011-11-22 | — | — | US | disclosed |
| US-20100233116-A1 | ORGANIC COMPOUNDS | XENON PHARMACEUTICALS INC. (CA) | 2010-09-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100233116-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | LMNA 2703/4885MEN1 4841/4885KMT2A 773/4885 |
| US-20120004164-A1 | ORGANIC COMPOUNDS | SCD, SCD5, FADS2 | LMNA 2176/4885MEN1 4876/4885KMT2A 2098/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.